KYTX Stock Summary and Trading Ideas (Kyverna Therapeutics | NASDAQ:KYTX)

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Kyverna Therapeutics trades on the NASDAQ stock market under the symbol KYTX.

As of June 1, 2026, KYTX stock price declined to $8.22 with 629,482 million shares trading.

KYTX has a beta of 1.63, meaning it tends to be more sensitive to market movements. KYTX has a correlation of 0.04 to the broad based SPY ETF.

KYTX has a market cap of $499.74 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that KYTX belongs to (by Net Assets): VTI, VXF, IBB, SCHA, DWAS.

KYTX has outperformed the market in the last year with a return of +222.4%, while the SPY ETF gained +30.0%. However, in the most recent history, KYTX shares have underperformed the stock market with its stock returning +0.1% in the last 3 month period and -3.7% for the last 2 week period, while SPY has returned +10.8% and +2.7%, respectively.

KYTX support price is $8.14 and resistance is $8.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYTX shares will trade within this expected range on the day.